Plain Language Summary
French nephrology highlights review covering 2025 advances including semaglutide's role in CKD management alongside novel therapies (atrasentan for IgA nephropathy, iptacopan for C3 glomerulopathy, obinutuzumab for lupus nephritis) and the proposed CKDx diagnostic framework. Contextualizes semaglutide's FLOW trial impact within the 2025 nephrology landscape. Provides a clinical synthesis of semaglutide's recognition as a breakthrough nephrology therapy in 2025—documenting its integration into the broader CKD therapeutic landscape alongside other novel kidney-protective agents for French nephrologists.
Abstract
In 2025, nephrology saw major advances in diagnosing and managing chronic kidney diseases. A new diagnostic framework, CKDx (chronic kidney disease of unexplained cause), was proposed to standardize patient evaluation by integrating genetic and histological tests. Therapeutic progress includes the demonstrated efficacy of atrasentan, an endothelin type A receptor antagonist, in IgA nephropathy, as well as that of iptacopan, an oral inhibitor of factor B, in IgA nephropathy and C3-deposit glomerulopathy. Obinutuzumab, a humanized anti-CD20 antibody, has also shown efficacy in lupus nephritis. Nephroprotective strategies, such as the finerenone-empagliflozin combination, have revealed significant benefits. Finally, emerging molecules such as baxdrostat, an aldosterone synthase inhibitor, and oral semaglutide, a GLP-1 analog, have demonstrated efficacy in resistant hypertension and in cardiovascular-risk reduction, respectively. These two molecules are currently being evaluated for preventing the progression of chronic kidney disease. However, challenges persist, including unequal access to innovative treatments, gaps in early screening, and the impact of climate change on kidney function. These results highlight the need for an integrated approach, combining innovation, equity, and adaptation to environmental changes to improve the care of patients with kidney diseases.